Bernd Dörken

33.7k total citations · 4 hit papers
412 papers, 22.0k citations indexed

About

Bernd Dörken is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Bernd Dörken has authored 412 papers receiving a total of 22.0k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Oncology, 139 papers in Molecular Biology and 117 papers in Immunology. Recurrent topics in Bernd Dörken's work include Lymphoma Diagnosis and Treatment (65 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Cell death mechanisms and regulation (50 papers). Bernd Dörken is often cited by papers focused on Lymphoma Diagnosis and Treatment (65 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Cell death mechanisms and regulation (50 papers). Bernd Dörken collaborates with scholars based in Germany, United States and Switzerland. Bernd Dörken's co-authors include Peter T. Daniel, Kurt Bommert, Stephan Mathas, Ralf C. Bargou, Markus Y. Mapara, Franziska Jundt, Harald Stein, Hanno Riess, Claus Scheidereit and Ioannis Anagnostopoulos and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Bernd Dörken

408 papers receiving 21.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncogene-induced senescence as an initial barrier in lymphoma development

2005 969 citations Bernd Dörken, Clemens A. Schmitt et al. profile →
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

1997 638 citations Florian Emmerich, Kurt Bommert et al. Journal of Clinical Investigation profile →
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

2003 538 citations Volker Diehl, Jeremy Franklin et al. profile →
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.

1996 508 citations Bernd Dörken et al. PubMed profile →

Peers

Countries citing papers authored by Bernd Dörken

Since Specialization

Citations

This map shows the geographic impact of Bernd Dörken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Dörken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Dörken more than expected).

Fields of papers citing papers by Bernd Dörken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Dörken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Dörken. The network helps show where Bernd Dörken may publish in the future.

Co-authorship network of co-authors of Bernd Dörken

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Dörken. A scholar is included among the top collaborators of Bernd Dörken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Dörken. Bernd Dörken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Transgenic Dual-Luciferase Reporter Mouse for Longitudinal and Functional Monitoring of T Cells In Vivo 2017 ·Cancer Immunology Research ·Martin Szyska, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bernd Dörken, Thomas Blankenstein, Il‐Kang Na	13
2	CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma 2016 ·Molecular Cancer Therapeutics ·J. Henry M. Däbritz, Yong Yu, Maja Milanovic, Martin Schönlein, Mathias T. Rosenfeldt, Jan R. Dörr, Andreas M. Kaufmann, Bernd Dörken, Clemens A. Schmitt	26
3	CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model 2016 ·Cancer Gene Therapy ·(unknown), (unknown), (unknown), Bernd Dörken, Antonio Pezzutto, Jörg Westermann	18
4	Access to Follicular Dendritic Cells Is a Pivotal Step in Murine Chronic Lymphocytic Leukemia B-cell Activation and Proliferation 2014 ·Cancer Discovery ·(unknown), (unknown), Michael Grau, (unknown), Ioannis Anagnostopoulos, Kerstin Gerlach, Raluca Niesner, Zoltán Cseresnyés, Anja E. Hauser, Peter Lenz, Thomas Hehlgans, Robert Brink, Jörg Westermann, Bernd Dörken, Martin Lipp, Georg Lenz, Armin Rehm, Uta E. Höpken	56
5	CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC 2012 ·Cancer Gene Therapy ·(unknown), Oliver Höhn, Duc Vu, Gerd Baldenhofer, Shakeel Ahmed, Bernd Dörken, Steve Norley, Martin Lipp, Antonio Pezzutto, Jörg Westermann	26
6	Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas 2011 ·Cancer Research ·Tara L. Naylor, Huaping Tang, Boris A. Ratsch, Andreas Enns, Alice Loo, Liqing Chen, Peter Lenz, Nigel J. Waters, W. Schüler, Bernd Dörken, Yung‐Mae Yao, Markus Warmuth, Georg Lenz, Frank Stegmeier	88
7	Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines 2011 ·Proceedings of the National Academy of Sciences ·Stephan Hailfinger, Hendrik Nogai, Christiane Pelzer, Maike Jaworski, (unknown), (unknown), (unknown), Chantal Décaillet, Michael Grau, Bernd Dörken, Peter Lenz, Georg Lenz, Margot Thome	179
8	CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model 2011 ·Cancer Gene Therapy ·(unknown), Gerd Baldenhofer, Shakeel Ahmed, (unknown), Duc Vu, Martin Lipp, Bernd Dörken, Antonio Pezzutto, Jörg Westermann	28
9	Reduced-Intensity Conditioning Using Fludarabine and Antithymocyte Globulin Alone Allows Stable Engraftment in a Patient with Dyskeratosis Congenita 2010 ·Acta Haematologica ·Lam Vuong, Philipp Hemmati, Stefan Neuburger, Theis H. Terwey, T. Vulliamy, Inderjeet Dokal, Philipp le Coutre, Bernd Dörken, R. Arnold	22
10	Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study 2009 ·Journal of Clinical Oncology ·Andreas Engert, Volker Diehl, Jeremy Franklin, Andreas Lohri, Bernd Dörken, Wolf‐Dieter Ludwig, P. Koch, Mathias Hänel, Michael Pfreundschuh, Martin Wilhelm, Lorenz Trümper, (unknown), Martin Bentz, Mathias Rummel, Orhan Sezer, Hans–Konrad Müller–Hermelink, Dirk Hasenclever, Markus Löffler	303
11	IκBα is required for marginal zone B cell lineage development 2008 ·European Journal of Immunology ·(unknown), Rudolf A. Rupec, Oliver Pabst, Ralf Ignatius, Reinhold Förster, Bernd Dörken, Franziska Jundt	4
12	Cellular senescence in cancer treatment: friend or foe? 2004 ·Journal of Clinical Investigation ·Pascal Kahlem, Bernd Dörken, Clemens A. Schmitt	95
13	Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms 2004 ·Leukemia ·Karin Schmelz, (unknown), Mandy Wagner, Michael Lübbert, Bernd Dörken, Ingo Tamm	102
14	Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells 2003 ·The Journal of Pathology ·Florian Emmerich, Sebastian Theurich, Michael Hummel, (unknown), (unknown), Konstanze Döhner, Kurt Bommert, Harald Stein, Bernd Dörken	105
15	The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines 2002 ·Oncogene ·Silke Radetzki, Claus‐Henning Köhne, Clarissa von Haefen, (unknown), Isrid Sturm, Bernd Dörken, Peter T. Daniel	3
16	The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines 2002 ·Oncogene ·Silke Radetzki, Claus‐Henning Köhne, Clarissa von Haefen, Bernhard Gillissen, Isrid Sturm, Bernd Dörken, Peter T. Daniel	52
17	The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL) - Results of a prospective randomized comparison of the German low grade study group (GLSG). 2001 ·Data Archiving and Networked Services (DANS) ·(unknown), Roswitha Forstpointner, F. Fiedler, Martin Gramatzki, Bernd Dörken, (unknown), Michael Kneba, M. Pfreundschuh, (unknown), (unknown), Martin Dreyling, (unknown)	0
18	Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. 2000 ·MDC Repository (Max-Delbrueck-Center for Molecular Medicine) ·Stephan Mathas, Anke Rickers, Kurt Bommert, Bernd Dörken, Markus Y. Mapara	127
19	Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. 1988 ·The Journal of Immunology ·Antonio Pezzutto, Peter S. Rabinovitch, Bernd Dörken, G Moldenhauer, Edward A. Clark	92
20	Selective Killing of Normal and Neoplastic Human B Cells with Anti-CD 19- and Anti-CD22-Ricin A Chain Immunotoxins 1986 ·PubMed ·Richard May, E S Vitetta, G Moldenhauer, Bernd Dörken	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact